Which other medication prescription on the client's medication list is most concerning to the nurse?

Prepare for the EDAPT Intracranial Regulation Test with interactive flashcards and multiple choice questions. Each question is accompanied by helpful hints and explanations to boost your readiness. Get started today and ensure your success!

Multiple Choice

Which other medication prescription on the client's medication list is most concerning to the nurse?

Explanation:
In managing intracranial regulation, the priority is avoiding medicines that could worsen CNS function or trigger seizures. Meperidine stands out because its breakdown product, normeperidine, can accumulate and cause CNS toxicity—tremors, agitation, confusion, and seizures. Seizures can raise intracranial pressure and worsen brain injury, making this drug the most concerning among the options, especially in patients with neurological compromise or renal impairment. The other medications listed are less problematic for acute brain status: acetaminophen is a safe analgesic with minimal CNS risk; lisinopril and atorvastatin are used for blood pressure control and cholesterol, respectively, and do not carry the same immediate risk of neurotoxicity or seizure that meperidine does.

In managing intracranial regulation, the priority is avoiding medicines that could worsen CNS function or trigger seizures. Meperidine stands out because its breakdown product, normeperidine, can accumulate and cause CNS toxicity—tremors, agitation, confusion, and seizures. Seizures can raise intracranial pressure and worsen brain injury, making this drug the most concerning among the options, especially in patients with neurological compromise or renal impairment.

The other medications listed are less problematic for acute brain status: acetaminophen is a safe analgesic with minimal CNS risk; lisinopril and atorvastatin are used for blood pressure control and cholesterol, respectively, and do not carry the same immediate risk of neurotoxicity or seizure that meperidine does.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy